Sunday, August 10, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Science Education

Gene therapy is halting cancer. Can it work against brain tumors?

April 19, 2024
in Science Education
Reading Time: 10 mins read
0
Gene therapy is halting cancer. Can it work against brain tumors?
68
SHARES
621
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

Grant of up to $11 million will fund a clinical trial at UCSF that uses a smarter new CAR-T guided by precision technology.  

Grant of up to $11 million will fund a clinical trial at UCSF that uses a smarter new CAR-T guided by precision technology.  

ADVERTISEMENT

A type of gene therapy called CAR-T that has extended survival for thousands of patients with leukemia and other blood cancers is being adapted at UC San Francisco to treat people with glioblastoma, the most common and deadly adult brain tumor. 
 
This new more powerful version of CAR-T employs a novel technology developed at UCSF called synthetic notch (synNotch) that both protects healthy tissue from damage and enables the treatment to work more effectively.  
 
UCSF opened enrollment this week for a clinical trial that is using the technology for the first time in people. A second trial, also at UCSF, is slated for 2025.  
 
 Approximately 12,000 Americans are diagnosed each year with glioblastoma. Patients survive on average for just 15 months after their diagnosis, and new treatments are urgently needed.  
 
“This project is a prime example of bench-to-bed translation within UCSF, representing the strengths in basic and clinical science, said Hideho Okada, MD, PhD, a physician-scientist and director of the UCSF Brain Tumor Immunotherapy Center. “We have a truly home-grown project here.” 
 
Okada has received up to $11 million for the first trial from the California Institute for Regenerative Medicine (CIRM), which funds stem cell and gene therapy research for incurable diseases and disorders through all stages of clinical trial development. 
 
Initial funding for the second trial is provided by the National Cancer Institute Specialized Programs of Research Excellence (NCI SPORE). 
 
“We hope that the treatment will prolong lives for patients with glioblastoma,” said Okada, who is a professor of neurosurgery at UCSF and a member of the Weill Institute for Neurosciences. “However, the primary goal of the current phase 1 study is to ensure safety and characterize any toxicities.”  
 
When tested in mice, Okada said the therapy provided a “robust and long-lasting result” that was more remarkable than anything he had encountered during 30 years of brain tumor research.  
 
A lasting therapy that is designed to reduce side effects 
 
The CIRM-funded trial will be led by principal investigator Jennifer Clarke, MD, MPH. It is open to patients with newly diagnosed glioblastoma, who have completed standard-of-care treatment. Tumors must have a mutation found in approximately 20% of glioblastomas, and that can be identified by the UCSF500 cancer gene panel test.  
 
The second study will be open to glioblastoma patients whether or not they have the mutation.  
 
CAR-T refers to chimeric antigen receptor T-cells, which are cancer-killing immune cells that have been extracted from the patient and genetically modified to recognize and destroy antigens that appear on the surface of cancer cells. These supercharged CAR-T cells are then infused back into the body to attack tumor cells.  
 
For many patients with leukemia and other blood cancers, CAR-T has demonstrated long-term remission, but the approach hasn’t worked against brain tumors. Glioblastoma cells are more diverse than blood cancer cells, and they can evade CAR-T. Many of the antigens made by the tumors are also found in healthy tissue, leaving them open to attack. 
 
To overcome these obstacles, Okada drew from the synNotch system developed by Wendell Lim, PhD, director of the UCSF Cell Design Institute and professor in the UCSF Department of Cellular and Molecular Pharmacology.  
 
The technology allowed scientists to program CAR-T cells to target specific antigens on tumor cells, without touching those found in healthy tissue. They also do not succumb to T-cell exhaustion, a common problem with CAR-T therapies, because they are more metabolically stable and use less energy to fight cancer longer. 
 
“We’ve created a system that is flexible and thorough and addresses the major concerns we’ve had about using CAR-T cells against solid tumors,” Lim said. “These cells act like computers: integrating multiple units of information and making complex decisions.” 

 

About UCSF: The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. UCSF Health, which serves as UCSF’s primary academic medical center, includes top-ranked specialty hospitals and other clinical programs, and has affiliations throughout the Bay Area. UCSF School of Medicine also has a regional campus in Fresno. Learn more at https://ucsf.edu, or see our Fact Sheet.

###

 

Follow UCSF
ucsf.edu | Facebook.com/ucsf | YouTube.com/ucsf

 

About the California Institute for Regenerative Medicine (CIRM)
At CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and act with a sense of urgency to succeed in that mission. To meet this challenge, our team of highly trained and experienced professionals actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of today’s most promising stem cell technologies. With $5.5 billion in funding and more than 150 active stem cell programs in our portfolio, CIRM is one of the world’s largest institutions dedicated to helping people by bringing the future of cellular medicine closer to reality. For more information go to www.cirm.ca.gov

 

 



Share27Tweet17
Previous Post

Roundtable showcases Warwick’s sustainable heat network system

Next Post

New copper-catalyzed C-H activation strategy from Scripps Research

Related Posts

blank
Science Education

Assessing Equity in Public Health Research: India & Australia

August 8, 2025
blank
Science Education

Education Research Groups Applaud Progress in Enhancing Civil Rights Data Collection

August 7, 2025
blank
Science Education

Evaluating the Cost-Effectiveness of COVID-19 Vaccination for U.S. Adults in 2023-2024

August 7, 2025
blank
Science Education

Technology can pinpoint the exact moments in videos when students are learning, according to a science magazine report.

August 7, 2025
blank
Science Education

Community Health Workers Boost Mental Care in Refugee Camps

August 7, 2025
blank
Science Education

Mount Sinai Researchers Create Innovative AI-Powered Surgical Training Model to Enhance Resident Education Quality

August 6, 2025
Next Post
New copper-catalyzed C-H activation strategy from Scripps Research

New copper-catalyzed C-H activation strategy from Scripps Research

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27531 shares
    Share 11009 Tweet 6881
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    945 shares
    Share 378 Tweet 236
  • Bee body mass, pathogens and local climate influence heat tolerance

    641 shares
    Share 256 Tweet 160
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    507 shares
    Share 203 Tweet 127
  • Warm seawater speeding up melting of ‘Doomsday Glacier,’ scientists warn

    310 shares
    Share 124 Tweet 78
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Black Hole-Neutron Star Binary Merges: Cosmic Catastrophe
  • Glueball Calculation’s Apparent Convergence: A New Light

  • Key Biophysical Rules for Mini-Protein Endosomal Escape
  • COVID-19 Survivors’ RICU Stories: Southern Iran Study

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.

Join 4,860 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine